- Home
- SOHO vs OTLK Comparison
SOHO vs OTLK Comparison
Compare SOHO & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SOHO | OTLK |
|---|---|---|
| Founded | 2004 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 43.8M | 42.3M |
| IPO Year | 2004 | 2016 |
Fundamental Metrics
Financial Performance| Metric | SOHO | OTLK |
|---|---|---|
| Price | $2.16 | $0.59 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $3.83 |
| AVG Volume (30 Days) | 93.7K | ★ 13.3M |
| Earning Date | 11-13-2025 | 02-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $177,571,118.00 | $1,413,535.00 |
| Revenue This Year | $13.93 | $2,048.59 |
| Revenue Next Year | N/A | $142.11 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.59 | $0.50 |
| 52 Week High | $2.20 | $3.39 |
Technical Indicators
Market Signals| Indicator | SOHO | OTLK |
|---|---|---|
| Relative Strength Index (RSI) | 55.58 | 25.44 |
| Support Level | $2.16 | $0.50 |
| Resistance Level | $2.20 | $0.65 |
| Average True Range (ATR) | 0.02 | 0.17 |
| MACD | -0.01 | -0.16 |
| Stochastic Oscillator | 50.00 | 5.58 |
Price Performance
Historical ComparisonAbout SOHO Sotherly Hotels Inc.
Sotherly Hotels Inc is engaged in Hotel operations. The company is a self-managed and self-administered lodging real estate investment trust that was formed to own, acquire, renovate, and reposition full-service, upscale, and upper-upscale hotel properties located in primary markets in the mid-Atlantic and southern United States. It generates revenue through the rooms, food, beverage, and other services. Geographically, the group has its presence in the regions of Florida, Georgia, Indiana, Maryland, North Carolina, Pennsylvania, Texas, and Virginia.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA, which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.